Solventum Corporation $SOLV Shares Sold by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. decreased its holdings in Solventum Corporation (NYSE:SOLV) by 23.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,680 shares of the company’s stock after selling 810 shares during the period. First Citizens Bank & Trust Co.’s holdings in Solventum were worth $203,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in SOLV. Rossby Financial LCC acquired a new stake in shares of Solventum in the first quarter valued at approximately $25,000. Strengthening Families & Communities LLC grew its holdings in Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares in the last quarter. Barrett & Company Inc. increased its stake in shares of Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after acquiring an additional 268 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in shares of Solventum during the 2nd quarter worth $31,000. Finally, Hara Capital LLC acquired a new position in shares of Solventum during the 1st quarter valued at about $38,000.

Solventum Stock Up 0.9%

Shares of NYSE:SOLV opened at $72.08 on Tuesday. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The stock has a market cap of $12.50 billion, a P/E ratio of 33.37, a P/E/G ratio of 2.91 and a beta of 0.50. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $85.92. The firm has a fifty day moving average price of $72.64 and a 200 day moving average price of $72.24.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 target price (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Wall Street Zen lowered shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a research report on Tuesday, July 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Solventum in a research note on Wednesday, October 8th. Finally, UBS Group initiated coverage on shares of Solventum in a research note on Wednesday, October 1st. They set a “neutral” rating and a $77.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Solventum has an average rating of “Hold” and an average price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.